Myriad reports analysis of HRD assay for breast cancer patients

Myriad Genetics Inc. (NASDAQ:MYGN) and researchers at Stanford University School of Medicine presented data on Friday from an analysis of the company's Homologous Recombination Deficiency (HRD) assay in 77 tumors from 76 breast cancer patients. The assay measures the number of defective breast cancer 1 early onset (BRCA1) and BRCA2 regions in a tumor sample. Researchers were evaluating the assay's ability to predict pathological response following neoadjuvant platinum-based therapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer in a Phase II trial. ...